{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:56Z","timestamp":1794047576081,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as an effective therapeutic option for selected patients with severe autoimmune diseases, particularly relapsingremitting multiple sclerosis. However, disease relapse remains a significant challenge, suggesting the persistence of autoreactive lymphocytes and incomplete restoration of sustained immune tolerance. Post-transplant cyclophosphamide (PTCy) is widely employed following allogeneic HSCT for graftversus- host disease prophylaxis. Here, we propose that incorporation of PTCy into auto-HSCT protocols may further improve outcomes in selected autoimmune disease patients by reducing and suppressing residual autoreactive T cells that survive conditioning and subsequently undergo lymphopenia-driven and \/ or antigen-induced proliferation post-transplant. Drawing on mechanistic and clinical insights from allogeneic transplantation, we discuss how PTCy could augment depletion of pathogenic effector T cells while supporting hematopoietic recovery and immune reconstitution. Because complete removal of autoreactive lymphocyte populations is unlikely, long-term disease control will probably require promoting peripheral immune regulation. Multiple sclerosis is highlighted as a model disease, although the concepts discussed may extend to other autoimmune disorders. Overall, the addition of PTCy to auto-HSCT represents a novel translational strategy with the potential to enhance immune resetting, suppress residual autoreactivity, and improve long-term remission rates in autoimmune disease patients.<\/jats:p>","DOI":"10.3324\/haematol.2026.301618","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:18:56Z","timestamp":1792048736000},"source":"Crossref","is-referenced-by-count":0,"title":["Could post-transplant cyclophosphamide benefit autoimmune disease patients following autologous hematopoietic stem cell transplantation?"],"prefix":"10.3324","author":[{"given":"Dietlinde","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,10,15]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14490\/80987","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14490\/80987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:15:47Z","timestamp":1794046547000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.301618","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}